Apomorphine in Parkinson's Disease Patients With Visual Hallucinations

Parkinson's Disease Clinical Trial

Official title: Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations

Status Recruiting

Clinical Trial Summary

This randomised, double-blind, placebo-controlled trial will evaluate the efficacy of continuous apomorphine infusion compared to placebo in PD patients with visual hallucinations, inadequately controlled with clozapine and cholinesterase inhibitors.

Clinical Trial Description

Introduction Visual hallucinations occur frequently in Parkinson's disease (PD). The prevalence of visual hallucinations ranges from 22 to 38%, increasing after long-term follow-up to more than 60%. Risk factors for visual hallucinations are age, disease duration, and cognitive impairment. The treatment of visual hallucinations is cumbersome and options are limited. Only clozapine has been proven to be efficacious without deteriorating the motor symptoms of PD. Instead of oral dopamine agonists and rotigotine, continuous infusion of apomorphine is well-tolerated in PD patients with cognitive impairments and/or visual hallucinations. Even beneficial effect of apomorphine on visual hallucinations are suggested, however there is lack of a randomized controlled trial.

The purpose of this randomised, double-blind, placebo-controlled trial is to evaluate the efficacy of continuous apomorphine infusion compared to placebo in PD patients with visual hallucinations, inadequately controlled with clozapine and cholinesterase inhibitors. ;

Related Conditions & MeSH terms

• Hallucinations
• Hallucinations, Visual
• Parkinson Disease
• Parkinson's Disease

• NCT number: NCT02702076
• Study type: Interventional
• Source: University Medical Center Groningen
• Contact: Robbert Borgemeester, MD
• Phone: +31 50 3611519
• Email: r.w.k.borgemeester@umcg.nl
• Status: Recruiting
• Phase: Phase 2
• Start date: May 2017
• Completion date: December 2017